Pharmacological subgroup
C10A – MITTEL, DIE DEN LIPIDSTOFFWECHSEL BEEINFLUSSEN, REIN
14Decisions
30Patient groups
Added benefit by patient group
- Minor1
- Non-quantifiable1
- Not proven28
Subgroups
Decisions, newest first
- 2026-05-21TryngolzaOlezarsenMinor
- 2024-07-04EvkeezaEvinacumabNot proven
- 2024-07-04EvkeezaEvinacumabNot proven
- 2024-06-06PraluentAlirocumabNot proven: 2 of 2 patient groups
- 2022-06-16RepathaEvolocumabNot proven: 4 of 4 patient groups
- 2022-05-05VazkepaIcosapent-EthylNot proven
- 2021-07-15LeqvioInclisiranNot proven: 2 of 2 patient groups
- 2021-04-15NilemdoBempedoinsäureNot proven: 2 of 2 patient groups
- 2020-02-20WaylivraVolanesorsenNon-quantifiable
- 2019-05-02PraluentAlirocumabNot proven: 4 of 4 patient groups
- 2018-09-06RepathaEvolocumabNot proven: 3 of 3 patient groups
- 2016-05-04PraluentAlirocumabNot proven
- 2016-03-09RepathaEvolocumabNot proven: 4 of 4 patient groups
- 2015-11-27LojuxtaLomitapidNot proven: 3 of 3 patient groups
Data status: 2026-10-29